These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

644 related items for PubMed ID: 33450318

  • 1. Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs.
    Suys EJA, Brundel DHS, Chalmers DK, Pouton CW, Porter CJH.
    J Control Release; 2021 Mar 10; 331():45-61. PubMed ID: 33450318
    [Abstract] [Full Text] [Related]

  • 2. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.
    Suys EJA, Chalmers DK, Pouton CW, Porter CJH.
    Mol Pharm; 2018 Jun 04; 15(6):2355-2371. PubMed ID: 29659287
    [Abstract] [Full Text] [Related]

  • 3. Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability.
    Tanaka Y, Nguyen TH, Suys EJA, Porter CJH.
    Mol Pharm; 2021 Apr 05; 18(4):1768-1778. PubMed ID: 33729806
    [Abstract] [Full Text] [Related]

  • 4. Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods.
    Crum MF, Trevaskis NL, Pouton CW, Porter CJ.
    Mol Pharm; 2017 Feb 06; 14(2):394-405. PubMed ID: 28002666
    [Abstract] [Full Text] [Related]

  • 5. In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.
    Devraj R, Williams HD, Warren DB, Mohsin K, Porter CJ, Pouton CW.
    Eur J Pharm Sci; 2013 Jul 16; 49(4):748-60. PubMed ID: 23684915
    [Abstract] [Full Text] [Related]

  • 6. Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway.
    Williams HD, Trevaskis NL, Yeap YY, Anby MU, Pouton CW, Porter CJ.
    Pharm Res; 2013 Dec 16; 30(12):2976-92. PubMed ID: 23824582
    [Abstract] [Full Text] [Related]

  • 7. Lipolysis-Permeation Setup for Simultaneous Study of Digestion and Absorption in Vitro.
    Keemink J, Mårtensson E, Bergström CAS.
    Mol Pharm; 2019 Mar 04; 16(3):921-930. PubMed ID: 30628771
    [Abstract] [Full Text] [Related]

  • 8. Quantifying In Vivo Luminal Drug Solubilization -Supersaturation-Precipitation Profiles to Explain the Performance of Lipid Based Formulations.
    Tanaka Y, Tay E, Nguyen TH, Porter CJH.
    Pharm Res; 2020 Feb 03; 37(3):47. PubMed ID: 32016597
    [Abstract] [Full Text] [Related]

  • 9. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations.
    Williams HD, Sassene P, Kleberg K, Calderone M, Igonin A, Jule E, Vertommen J, Blundell R, Benameur H, Müllertz A, Pouton CW, Porter CJ, LFCS Consortium.
    Pharm Res; 2013 Dec 03; 30(12):3059-76. PubMed ID: 23661145
    [Abstract] [Full Text] [Related]

  • 10. Effects of Lipid Digestion and Drug Permeation/Re-Dissolution on Absorption of Orally Administered Ritonavir as Different Lipid-Based Formulations.
    Tanaka Y, Doi H, Katano T, Kasaoka S.
    Eur J Pharm Sci; 2021 Feb 01; 157():105604. PubMed ID: 33098990
    [Abstract] [Full Text] [Related]

  • 11. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.
    McEvoy CL, Trevaskis NL, Feeney OM, Edwards GA, Perlman ME, Ambler CM, Porter CJH.
    Mol Pharm; 2017 Dec 04; 14(12):4525-4538. PubMed ID: 29076741
    [Abstract] [Full Text] [Related]

  • 12. Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation?
    Alskär LC, Parrow A, Keemink J, Johansson P, Abrahamsson B, Bergström CAS.
    J Control Release; 2019 Jun 28; 304():90-100. PubMed ID: 31047962
    [Abstract] [Full Text] [Related]

  • 13. A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations.
    Crum MF, Trevaskis NL, Williams HD, Pouton CW, Porter CJ.
    Pharm Res; 2016 Apr 28; 33(4):970-82. PubMed ID: 26703975
    [Abstract] [Full Text] [Related]

  • 14. Biopharmaceutical modeling of drug supersaturation during lipid-based formulation digestion considering an absorption sink.
    Stillhart C, Imanidis G, Griffin BT, Kuentz M.
    Pharm Res; 2014 Dec 28; 31(12):3426-44. PubMed ID: 24962509
    [Abstract] [Full Text] [Related]

  • 15. 50years of oral lipid-based formulations: Provenance, progress and future perspectives.
    Feeney OM, Crum MF, McEvoy CL, Trevaskis NL, Williams HD, Pouton CW, Charman WN, Bergström CAS, Porter CJH.
    Adv Drug Deliv Rev; 2016 Jun 01; 101():167-194. PubMed ID: 27089810
    [Abstract] [Full Text] [Related]

  • 16. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.
    Williams HD, Sassene P, Kleberg K, Calderone M, Igonin A, Jule E, Vertommen J, Blundell R, Benameur H, Müllertz A, Porter CJ, Pouton CW, Communicated on Behalf of the LFCS Consortium.
    J Pharm Sci; 2014 Aug 01; 103(8):2441-55. PubMed ID: 24985238
    [Abstract] [Full Text] [Related]

  • 17. Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation.
    Yeap YY, Trevaskis NL, Quach T, Tso P, Charman WN, Porter CJ.
    Mol Pharm; 2013 May 06; 10(5):1874-89. PubMed ID: 23480483
    [Abstract] [Full Text] [Related]

  • 18. The potential for drug supersaturation during intestinal processing of lipid-based formulations may be enhanced for basic drugs.
    Yeap YY, Trevaskis NL, Porter CJ.
    Mol Pharm; 2013 Jul 01; 10(7):2601-15. PubMed ID: 23697606
    [Abstract] [Full Text] [Related]

  • 19. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
    Feeney OM, Williams HD, Pouton CW, Porter CJ.
    J Control Release; 2014 Oct 28; 192():219-27. PubMed ID: 25058571
    [Abstract] [Full Text] [Related]

  • 20. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.
    Williams HD, Anby MU, Sassene P, Kleberg K, Bakala-N'Goma JC, Calderone M, Jannin V, Igonin A, Partheil A, Marchaud D, Jule E, Vertommen J, Maio M, Blundell R, Benameur H, Carrière F, Müllertz A, Pouton CW, Porter CJ.
    Mol Pharm; 2012 Nov 05; 9(11):3286-300. PubMed ID: 23030411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.